CNTA 📈 Centessa Pharmaceuticals ADR - Overview

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to improve patients' lives.

The company's pipeline is rich in promising products, including SerpinPC, an activated protein C inhibitor designed to treat hemophilia A and B, two debilitating bleeding disorders. Another key product is ORX750, an orally administered OX2R agonist that targets narcolepsy and other sleep disorders, aiming to restore normal sleep patterns and improve quality of life.

Centessa Pharmaceuticals is also advancing LB101, a bi-specific monoclonal antibody that tackles solid tumors by selectively driving potent CD47 and CD3 effector function activity while minimizing systemic toxicity. This approach has the potential to revolutionize cancer treatment by reducing side effects and improving outcomes.

In addition to these late-stage programs, the company is developing a range of OX2R Agonists compounds to address narcolepsy and other sleep disorders. Its pipeline also includes earlier-stage preclinical assets and discovery-stage programs, showcasing the company's commitment to innovation and growth.

Headquartered in Altrincham, the United Kingdom, Centessa Pharmaceuticals plc was founded in 2020 with a mission to transform the pharmaceutical industry through cutting-edge science and collaboration. For more information, visit their website at https://www.centessa.com.